We are pleased to announce a successful scientific Advisory Board meeting held during the American Society of Clinical Oncology (ASCO) Annual Meeting 2024. Click here to learn more! https://lnkd.in/ecaCntWT
Starton Therapeutics’ Post
More Relevant Posts
-
Hello Boston. Translational Drug Development (TD2) is at Clinical Trials in Oncology East Coast. Visit our booth and learn how TD2 can help advance your cancer therapeutic program (from bench to bedside). While I won't be there (why did I hear a huge sigh of relief 😉), my colleague Parris Johnson is the man you want to speak with anyway. Don't worry, I'll be back for Tumor Models Boston in a couple weeks. #clinicaltrials #cancertherapeutic #oncology #tumormodelsboston #tumormodels #clinicaldevelopment #preclinical
Today's the day, TD2 is live in Boston at Clinical Trials in Oncology East Coast! Stop by to learn about our latest advancements in oncology research or follow the link to schedule a meeting: https://hubs.li/Q02FhSPg0
-
-
Are you aware of the recent implementation of the EU Clinical Trials Regulation No 536/2014 and how that will affect your oncology program? Find out in my team members’ blog: https://bit.ly/4d8eHdy
-
-
Recent changes including EUCTR and IVDR are all well intended, but remain to fully realize their benefit. Related delays and other inadvertent consequences contribute to the reduction in availability of trials in for patients across Europe...
IQVIA Institute’s Pre-ESMO Symposium tackled how to strengthen Europe’s position as a global leader in oncology trials. Rewatch this crucial conversation—download the webinar here https://bit.ly/4dlkLiw. #ESMO2024
-
-
NEW SOCRA Blog: Take a look inside the 2024 SOCRA Oncology Clinical Trials Conference. Program Chairs Tammy Neseth & Susanna Sellmann discuss the upcoming conference in San Antonio, TX March 13-15, 2024. Read the Blog Here: https://smpl.is/8gbyv Learn More About the Oncology Conference: https://smpl.is/8gbyw #socra #clinicalresearcheducation #oncologyclinicaltrials
-
-
Are you aware of the recent implementation of the EU Clinical Trials Regulation No 536/2014 and how that will affect your oncology program? Find out in my team members’ blog: https://bit.ly/3Yws1UO
-
-
Consultant in the department of Gynecological oncology in Amrita with special interest in ROBOTIC, HIPEC, PIPAC .
#oncology https://lnkd.in/gpd3J-Bg Abstract presentation at the Young leaders in Oncology session.
-
📢 Attention: still chance ⌚ to sign up for this upcoming webinar! ❗ Don't miss how #JamesMatcham and #MichaelFossler will delve into the key objectives of early oncology development, focusing on the estimation of the recommended Phase 2 dose (RP2D) and the identification of optimal patient populations for further research. 👇 Key Topics: - Dose Escalation Design Options - Basket Study Design Options - PK/PD Modelling for identifying the RP2D #cytel #clinicaldevelopment #oncology
Two more days until our webinar "Project Optimus: Dose Escalation and Stratification Designs in Early Oncology Development" with James Matcham and Mike Fossler! Click here to register: https://hubs.ly/Q02BSNR00 #OncologyTrials #BasketTrials #Bayesian
-
-
Today, we announced a poster presentation at the American Society of Clinical Oncology (ASCO)) annual meeting highlighting interim results from the ongoing Phase 1 ELiPSE-1 study of CNTY-101 in relapsed or refractory (R/R) #lymphoma. The poster showcases CNTY-101’s continued encouraging preliminary efficacy and manageable safety profile for with no observed DLTs or GvHD. Learn more: https://bit.ly/3RaEI3k #ASCO2024
-
-
🚀 Volume 2 Issue 2, June 2024 of Oncology Advances has been published. Special thanks to ⭐Prof. Ruiwen Zhang and all authors and reviewers for their contributions and support! 🔗 Read more: https://lnkd.in/gzJYnPZU
-
